INmune Bio (NASDAQ: INMB), a clinical-stage immunology
company focused on developing treatments that harness the patient’s innate
immune system to fight disease, today announced its receipt of United States
Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent
Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND
THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR,” covers INmune’s INB03
Program that utilizes dominant negative TNFα (“DN-TNFα”) technology for
treating cancer. “This is an important patent for INmune Bio, Inc. and provides
exclusivity for use of our DN-TNFα technology for the treatment of cancer,”
INmune Bio Assoc. General Counsel Joshua Schoonover said in the news release.
“With the approval from the USPTO, and the positive indication of allowable
subject matter in the international preliminary report on patentability for the
corresponding international PCT patent application, published as
WO/2017/106278, we expect this patent family should develop into global
intellectual property rights.”
To view the full press release, visit http://ibn.fm/r6n5k
About INmune Bio, Inc.
INmune Bio, Inc. is a clinical-stage immunology company
developing therapies targeting the innate immune system to fight disease.
INmune Bio is developing two product platforms, the DN-TNFα Platform and an
Immune Priming Platform, as well as multiple products related to these
platforms that reengineer the patient’s innate immune system’s response to
disease. In addition to INB03, the DN-TNFα Platform includes XPRO1595, a
DN-TNFα protein biologic that targets soluble TNFα (sTNFα) and may have many
beneficial effects in patients with Alzheimer’s disease by decreasing
neuroinflammation; and NeuLiv, also a DN-TNFα protein biologic that may enable
targeting of the underlying cause of non-alcoholic steatohepatitis (NASH), to
help stop the disease and allow the liver to heal. The Immune Priming Platform
includes INKmune, which is a natural killer (NK) cell therapeutic that primes
the patient’s NK cells to attack minimal residual disease, the remaining cancer
cells that are difficult to detect, which often cause relapse. INmune Bio’s
product platforms utilize a precision medicine approach for the treatment of a
wide variety of hematologic malignancies, solid tumors and neurodegenerative
diseases. For more information, visit the company’s website at www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
